CRISPR Therapeutics Past Earnings Performance

Past criteria checks 0/6

CRISPR Therapeutics's earnings have been declining at an average annual rate of -27%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 7% per year.

Key information

-27.0%

Earnings growth rate

-25.1%

EPS growth rate

Biotechs Industry Growth	11.5%
Revenue growth rate	-7.0%
Return on equity	-12.4%
Net Margin	-118.1%
Last Earnings Update	30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How CRISPR Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

LSE:0VRQ Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
30 Sep 24	203	-240	71
30 Jun 24	202	-266	72
31 Mar 24	272	-217	72
31 Dec 23	371	-154	76
30 Sep 23	170	-354	81
30 Jun 23	170	-416	90
31 Mar 23	100	-524	97
31 Dec 22	1	-650	102
30 Sep 22	14	-681	105
30 Jun 22	15	-633	102
31 Mar 22	915	312	103
31 Dec 21	915	378	100
30 Sep 21	902	412	102
30 Jun 21	902	447	100
31 Mar 21	1	-392	93
31 Dec 20	1	-349	86
30 Sep 20	77	-211	80
30 Jun 20	289	20	74
31 Mar 20	289	46	68
31 Dec 19	290	67	63
30 Sep 19	213	-11	63
30 Jun 19	1	-200	57
31 Mar 19	2	-185	54
31 Dec 18	3	-165	48
30 Sep 18	35	-117	43
30 Jun 18	37	-91	41
31 Mar 18	40	-75	36
31 Dec 17	41	-68	36
30 Sep 17	11	-51	35
30 Jun 17	10	-41	31
31 Mar 17	7	-36	32
31 Dec 16	5	-23	31
30 Sep 16	3	-53	25
30 Jun 16	2	-44	24
31 Mar 16	1	-31	17
31 Dec 15	0	-26	13

Quality Earnings: 0VRQ is currently unprofitable.

Growing Profit Margin: 0VRQ is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 0VRQ is unprofitable, and losses have increased over the past 5 years at a rate of 27% per year.

Accelerating Growth: Unable to compare 0VRQ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0VRQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).

Return on Equity

High ROE: 0VRQ has a negative Return on Equity (-12.35%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 22:57
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CRISPR Therapeutics AG is covered by 46 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jack Allen	Baird
Huidong Wang	Barclays
Evan Seigerman	BMO Capital Markets Equity Research

CRISPR Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

Recent updates

Crispr Therapeutics Presents Data from the Their Ongoing Phase 1/2 Dose Escalation Clinical Trial Evaluating the Safety and Efficacy of Ctx112

New minor risk - Share price stability

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 22% undervalued after recent price drop

New minor risk - Shareholder dilution

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

New minor risk - Share price stability

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

Now 23% undervalued after recent price drop

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

Now 20% undervalued

Full year 2022 earnings released: US$8.36 loss per share (vs US$4.97 profit in FY 2021)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

Third quarter 2022 earnings released: US$2.24 loss per share (vs US$1.67 loss in 3Q 2021)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

Now 22% undervalued after recent price drop

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

Investor sentiment deteriorated over the past week

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell Malignancies

Third quarter 2021 earnings released: US$1.67 loss per share (vs US$1.32 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$10.01 (vs US$1.30 loss in 2Q 2020)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Presents New Data in 22 Patients with Greater Than 3 Months Follow-Up Post-Treatment with Investigational Crispr/Cas9 Gene-Editing Therapy

First quarter 2021 earnings released: US$1.51 loss per share (vs US$1.15 loss in 1Q 2020)

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources